New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 4, 2014
06:23 EDTAKRXAkorn guidance 'not a cause for alarm,' says Piper Jaffray
Piper Jaffray believes Akorn's 2014 guidance is "not a cause for alarm" given the depth of the company's pipeline. Piper says Akorn's long-term growth story remains intact and it keeps an Overweight rating on the stock despite lowering its price target for shares to $28 from $29.
News For AKRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 9, 2014
10:23 EDTAKRXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:11 EDTAKRXAkorn initiated with Outperform, $50 target at William Blair
William Blair started shares of Akorn with an Outperform rating and $50 price target. The firm says the maker of ophthalmic and hospital-based injectable therapies is one of the fastest-growing companies in the specialty pharmaceuticals sector. William Blair thinks consolidation will likely continue within the specialty/generics market and feels Akorn represents an attractive asset. The stock closed yesterday up 38c to $39.75.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use